Primary Treatment: BXQ-350 · No Placebo Group · Phase 1
Experimental Group · 1 Intervention: BXQ-350 · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
Screening: ~3 weeks
Reporting: from date of bxq-350 treatment completion until time of death from any cause; up to approximately 5 years
Who is running the clinical trial?
CTI Clinical Trial and Consulting ServicesOTHER
31 Previous Clinical Trials
3,458 Total Patients Enrolled
Bexion Pharmaceuticals, Inc.Lead Sponsor
5 Previous Clinical Trials
332 Total Patients Enrolled
Age Any Age · All Participants · 7 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have completed the End of Study visit of the prior Bexion-sponsored BXQ-350 clinical study.
The investigator believes that continued treatment with BXQ-350 is clinically appropriate for the subject.
You have completed the required study observation period or time of closure for a prior BXQ-350 clinical study.
You are a female of child bearing potential (FCBP) and you have a negative serum pregnancy test result within 28 days prior to the first continuing treatment assessment for females of child bearing potential (FCBP).
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.